AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

LEXX · NASDAQ · Biotechnology

Lexaria Bioscience

Developer and licensor of DehydraTECH oral drug-delivery technology.

$10.30

After-hours close−0.11 (−1.03%)

At close$10.41(−10.87%)

Something off on this page? Send us feedback.

Profile

Lexaria Bioscience Corp.LEXXHealth Care

Licenses DehydraTECH, a patent-based oral drug-delivery platform applied to GLP-1 medicines, investigational cannabidiol, nicotine and consumer ingredients. Revenue depends on technology fees, royalties, research support and partner agreements rather than an approved-drug sales base.

Develops and licenses DehydraTECH, a lipid-based formulation and processing platform designed to improve the oral delivery characteristics of active ingredients. Its reusable assets are patents, recipes and know-how rather than manufacturing capacity or a direct sales force.

Applies the platform to GLP-1 medicines, investigational cannabidiol for hypertension, nicotine and selected consumer or bioactive ingredients. Headquarters and central management are in Kelowna, Canada, while the Nevada issuer trades in the United States; patents, studies and vendors span multiple jurisdictions.

Generates prospective economics from license fees, royalties, research support, milestones and pharmaceutical partnerships. Each active ingredient and indication requires its own evidence and, where relevant, regulatory authorization, while growth depends on counterparties converting platform interest into agreements.

Company facts

CEOChristopher Bunka

ListedJan 12, 2021

ExchangeNASDAQ

HeadquartersKelowna, Canada

CountryCanada

Employees7

CIK0001348362

ISINUS52886N6040

Key statistics

Market cap$17.1M

EPS (ttm)−$5.32

P/E (ttm)−1.95

ROE-160.7%

P/B3.61

P/S88.16

Dividend yield—

Beta0.65vs XLV −0.17

Year to date +6.1% · Average volume (30d) 45.9K

Analysts

Price target, next 12 months$1.50−85.5%Median of 2 analysts · vs the Aug 28 close

ConsensusBuy2 of 2 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $10.35

High$1.50−85.5%

Median$1.50−85.5%

Low$1.50−85.5%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Target
Dec 26, 2025	H.C. Wainwright	Target	$1.50

Earnings

EPS

Estimate−$0.90

ReportedDue Oct 28, 2026

Revenue

Estimate$50.0K

ReportedDue Oct 28, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jul 13, 2026Q3 FY26	−$0.90	−$1.20	−33.3%	$50.0K	—	—	−1.23%
Apr 13, 2026Q2 FY26	−$0.10	−$0.06	+40.0%	$50.0K	$20.0K	−60.0%	+4.08%
Jan 16, 2026Q1 FY26	−$1.95	−$0.07	+96.4%	$100.0K	—	—	−2.99%
Jan 13, 2026Q1 FY26	−$0.13	−$0.07	+46.2%	$100.0K	—	—	−3.38%

View details

Financial highlights

	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Revenue	$174.0K	$174.0K	$174.0K	$0	$20.0K	$0
Gross profit	$174.0K	$174.0K	$174.0K	$0	$20.0K	$0
Operating income	−$2.8M	−$3.8M	−$2.7M	−$1.6M	−$1.5M	−$2.0M
Net income	−$2.7M	−$3.8M	−$2.7M	−$1.6M	−$1.4M	−$2.0M
Diluted EPS	−$2.25	−$3.15	−$2.10	−$1.12	−$0.90	−$1.20
Gross margin	100.0%	100.0%	100.0%	—	100.0%	—
Operating margin	-1,581.0%	-2,155.4%	-1,545.2%	—	-7,259.5%	—

Fiscal years (4-quarter sums)FY21 $722.7K · FY22 $255.4K · FY23 $192.0K · FY24 $464.3K · FY25 $705.9K

Revenue by product · Q3 FY26

IP Licensing$20.0K · 100%

Balance sheet, May 31, 2026Cash & short-term investments $3.6M · Total debt $86.7K · Total assets $4.8M · Shareholders' equity $4.7M

Dividends

No dividends on record.

Ownership

Institutions 6.01%99.4K sharesInsiders 2.60%43.0K sharesOther 91.39%1.51M shares

Shares outstanding 1.65M · Float 1.60M · 97.0% free float

Insider tradesForm 4

No open-market trades in the last 12 months.